Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Solid Tumors 1Sarcoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Liver Neoplasms 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Esophageal Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Nivolumab 74Sunitinib 73pembrolizumab 49Everolimus 39Sorafenib 36Bevacizumab 36Axitinib 36cabozantinib 35Radiosurgery 33Ipilimumab 33pazopanib 32Magnetic Resonance Spectroscopy 27Interleukin-2 27aldesleukin 23Specimen Handling 22Cyclophosphamide 21lenvatinib 20fludarabine phosphate 17Radiotherapy 16Interferon-alpha 15Peripheral Blood Stem Cell Transplantation 14Gemcitabine 14Biopsy 14temsirolimus 13Nephrectomy 13durvalumab 11Immunohistochemistry 11CTLA-4 Antigen 11Blood Specimen Collection 11Capecitabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Renal Cell × TH 302 × Clear all
NCT01497444 2020-02-06

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

Alliance for Clinical Trials in Oncology

Phase 1 Completed
24 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡